Alzheimer's Drug Discovery Foundation

Modulo Bio simulates the neuroimmune system to identify medication candidates that target microglia, and the company combines stem cell biology, neuroscience, software, automation, and artificial intelligence to create neuroimmune microenvironments from stem cells and to manipulate and measure the neuroimmune system in cell models and patient samples, enabling researchers to discover new treatments for neurodegenerative diseases.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

The University of Gothenburg, established in 1891, is a prominent non-endowment institution located in Gothenburg, Sweden. It is dedicated to societal advancement and aims to foster a sustainable world through education and research. The university engages actively in public discourse and maintains ongoing dialogues with the surrounding community, both nationally and internationally. It encompasses various faculties, including the School of Business, Economics and Law, which contributes to its diverse academic offerings. Through its commitment to knowledge exchange, the University of Gothenburg plays a vital role in addressing contemporary challenges and promoting innovation in society.

GLX Analytix combines proprietary blood biomarkers with AI to pioneer personalized medicine. Its platform enables earlier diagnosis and optimized treatment plans for various diseases such as neurodegeneration, autoimmunity, cardiovascular disorders, and neuropsychiatric conditions.

Founded in 2007 by scientists from Washington University School of Medicine and LifeTech Research, C2N Diagnostics specializes in protein diagnostic testing services for neurological disorders. Utilizing mass spectrometry-based analysis, the company aims to provide accurate and sensitive diagnostics for conditions like Alzheimer's disease.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

RetiSpec is developing a non-invasive eye scanner for the early detection of Alzheimer’s Disease pathology years before symptoms occur. This enables clinicians to intervene with emerging therapeutics at an earlier stage when there's a chance of impacting the disease.

Coya Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies that enhance the function of regulatory T cells (Tregs) in vivo. The company is advancing multiple first-in-class and best-in-class approaches, including allogeneic Treg-derived exosome therapeutics and novel biologics. Coya's proprietary medicinal products are designed to modulate Treg function, targeting a range of conditions such as neurodegenerative, autoimmune, and metabolic diseases. By harnessing the therapeutic potential of Tregs, Coya Therapeutics aims to address significant unmet medical needs in these critical areas of health.

NeuroAge Therapeutics is a biotechnology company focused on longevity and neuroscience. It develops novel pharmaceuticals to slow or reverse biological brain aging and treat neurodegenerative diseases, leveraging machine learning and an aging clock technology.

Superfluid DX is a company focused on developing advanced molecular diagnostics technology aimed at early disease detection and monitoring. By leveraging innovative research in transcriptomics, Superfluid DX analyzes tissue-specific cell-free circulating RNA found in blood samples. This non-invasive approach enables the identification of genetic information linked to neurodegenerative diseases and other conditions, providing healthcare professionals with critical insights into a patient's health status. The company's platform is designed to facilitate early diagnosis and ongoing monitoring of organ damage, ultimately improving patient outcomes by enabling timely interventions.

GliaPharm is a Swiss biotechnology company focused on developing treatments for neurological and psychiatric disorders by targeting glial cells to support brain metabolism. It has developed the GliaX platform to identify drugs that modulate glial activity and energy metabolism. The platform combines high-throughput screening using enzymatic and primary-cell assays with metabolic characterization of compounds in vitro in primary brain cell cultures and in vivo in rodent brains. Research includes various rodent models of brain aging, Alzheimer's disease, and ALS, with selective contract research organizations handling parts of the drug-development process. Founded in 2016 and based in Geneva, GliaPharm pursues glia-mediated neuroprotection and maintenance of cognitive function.

Imeka Solutions Inc., established in 2011 and based in Sherbrooke, Canada, specializes in medical image processing services. It provides advanced MRI-based techniques such as diffusion tensor imaging, tractography, and free water imaging to clients including neurologists, clinicians, and pharmaceutical researchers. Imeka's platform leverages deep learning algorithms and high-resolution MRI structures to quantify and understand brain connectivity, particularly white matter, aiding in neuroinflammation and demyelination research.

CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

BrainScope Company develops non-invasive medical devices to aid professionals in assessing traumatic brain injuries. Its flagship product, BrainScope One, uses electroencephalogram signals and advanced algorithms to objectively determine the likelihood of concussion presence and severity. Serving military markets, emergency departments, and sports sectors worldwide.

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on advancing brain health through innovative diagnostic tools and therapies for neurodegenerative diseases. Founded in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, Aprinoia develops imaging-based diagnostics, including 18F-PM-PBB3, a tau positron-emission tomography (PET) tracer that aids in the diagnosis of tauopathies. The company also manufactures an alpha-synuclein PET imaging tracer. By targeting protein aggregates associated with conditions like Alzheimer's and Parkinson's diseases, Aprinoia aims to enhance precision medicine in neuroscience and improve patient outcomes. The company's commitment to addressing the complexities of neurodegenerative diseases positions it as a leader in the development of first-in-class and best-in-class diagnostic and therapeutic solutions.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries, concussions, acute ischemic strokes, and neurodegenerative disorders like Alzheimer’s disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selective astrocyte activation. Its lead product, AST-004, is a novel small molecule designed for acute administration that protects and repairs damaged neurons by selectively stimulating astrocytes. Astrocyte Pharmaceuticals aims to advance innovative therapeutic agents to improve recovery and well-being for patients suffering from brain injuries.

ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

ALZpath is a biotechnology company specializing in innovative diagnostic solutions for Alzheimer's disease. It offers laboratory research services, including early-stage diagnosis through blood tests measuring pTau217 levels, and personalized treatment interventions to enhance detection and improve patient outcomes.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

ToxGenSolutions is a biotechnology company that specializes in developing diagnostic tools for preclinical diagnostics, particularly targeting Alzheimer's Disease. The company employs (epi-)genetic approaches to address molecular initiation events and key adverse outcome pathways associated with various pathologies, including neurodegeneration, cancer, and immune dysfunction. By focusing on mechanism-based genetic signatures, ToxGenSolutions aims to identify and classify new leads and toxicants during the drug screening and development process. This innovative approach enables healthcare professionals to intervene early in the disease progression, ultimately enhancing safety assessments and improving therapeutic strategies in drug development.

Imaginostics develops noninvasive quantitative imaging tools for precision medicine and neurology. Its MRI-based technology provides detailed vascular visualization and quantitative measurements of vascular structure, function, and leakage, using safe contrast alternatives and is compatible with existing MRI scanners. The company offers biomarker solutions to the pharmaceutical industry through contract research organizations and participates in preclinical and clinical research with researchers at leading institutions. Its imaging solutions support the diagnosis and monitoring of neurological disorders, renal conditions, chronic diseases, and acute injuries such as traumatic brain injury or stroke, enabling hospitals to quantify physiology, track disease progression, and assess the effects of drugs on the body.

Superfluid DX is a company focused on developing advanced molecular diagnostics technology aimed at early disease detection and monitoring. By leveraging innovative research in transcriptomics, Superfluid DX analyzes tissue-specific cell-free circulating RNA found in blood samples. This non-invasive approach enables the identification of genetic information linked to neurodegenerative diseases and other conditions, providing healthcare professionals with critical insights into a patient's health status. The company's platform is designed to facilitate early diagnosis and ongoing monitoring of organ damage, ultimately improving patient outcomes by enabling timely interventions.

Quanterix is a life sciences company that develops an ultra-sensitive digital immunoassay platform to advance precision health for research and diagnostics. Its Simoa platform employs bead-based and planar array technologies to detect protein biomarkers at very low concentrations in blood, serum, and other fluids that are undetectable by conventional assays. This enables early disease detection, improved prognosis, and more informed treatment decisions in clinical settings and research. The company provides instruments, assay kits, LDTs and assay services, as well as specialized modules and systems such as HD-X automated immunoassay analyzer, aiming to support biomarker analysis across healthcare and life science applications.

Optina Diagnostics is a diagnostics company focusing on retinal imaging and artificial intelligence to provide non-invasive tests that detect signs of neurodegenerative and ocular diseases. By analyzing retinal images, it identifies biomarkers associated with Alzheimer's disease, as well as eye conditions like age-related macular degeneration and diabetic retinopathy, enabling clinicians to assess brain health and disease risk early. The platform aims to support timely diagnosis and treatment decisions with a simple eye exam.

MindImmune Therapeutics is a pharmaceutical company that develops antibody-based therapies targeting the immune system to treat diseases of the central nervous system. Its programs aim to address neuroinflammation associated with brain disorders such as Alzheimer's disease, Huntington's disease, pain, and psychiatric conditions. The company emphasizes the role of immune dysfunction in CNS pathology and seeks to inhibit peripheral innate immune responses to produce therapeutic effects. Based in Kingston, Rhode Island, MindImmune pursues collaborations with neuroscience research institutions to advance its drug development initiatives.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

NeuroVision Imaging is a neuroscience company that develops diagnostic tests and biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s disease. It has developed a retinal imaging technology that is low-cost, non-invasive, and capable of measuring retinal autofluorescence to assess amyloid-beta plaque accumulation in the brain, enabling physicians to diagnose Alzheimer’s disease more efficiently. The company also provides data aggregation, analysis, biostatistics, and machine learning applications to large repositories of images and biomarker data to advance understanding and prediction of neurodegenerative diseases. It serves customers in the United States and internationally and was founded in 2010, with its headquarters in Sacramento, California.

C. Light Technologies is a neurotech company developing a retinal eye-tracking platform and integrated hardware and software that monitor neurological health. The system uses machine learning to analyze retinal imaging captured by a scanning laser ophthalmoscope, enabling objective assessment of neurological activity and disease progression. The initial focus is on multiple sclerosis and other neurodegenerative conditions, aiming to improve monitoring and diagnosis. The company combines advanced imaging with algorithms to provide precise tracking of retinal function, supporting clinicians in evaluating neurological health over time. Founded in 2014 and based in Berkeley, California.

NeuroVision Imaging is a neuroscience company that develops diagnostic tests and biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s disease. It has developed a retinal imaging technology that is low-cost, non-invasive, and capable of measuring retinal autofluorescence to assess amyloid-beta plaque accumulation in the brain, enabling physicians to diagnose Alzheimer’s disease more efficiently. The company also provides data aggregation, analysis, biostatistics, and machine learning applications to large repositories of images and biomarker data to advance understanding and prediction of neurodegenerative diseases. It serves customers in the United States and internationally and was founded in 2010, with its headquarters in Sacramento, California.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.

Founded in 2007 by scientists from Washington University School of Medicine and LifeTech Research, C2N Diagnostics specializes in protein diagnostic testing services for neurological disorders. Utilizing mass spectrometry-based analysis, the company aims to provide accurate and sensitive diagnostics for conditions like Alzheimer's disease.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, that specializes in developing a proprietary technology platform for the direct and selective capture of large necrotic particles from physiological solutions such as whole blood, serum, and plasma. This platform facilitates the detection of diseases, particularly cancers, in their earliest stages by enabling access to native-state biomarkers and nanoparticles for multiomics applications. The company offers various products and services, including the TR(ACE) Assay for monitoring treatment responses in cancer, tissue-based molecular and cfDNA liquid biopsy testing for personalized medicine, and a biomarkers program aimed at drug development for Alzheimer's disease. Additionally, Biological Dynamics provides clinical laboratory services, including molecular and next-generation sequencing, and supports applications in autoimmune diseases, transplant rejection, and traumatic brain injury. Founded in 2008, the company is dedicated to improving global health outcomes through innovative diagnostic solutions.

Vaccinex is a biotechnology company focused on developing therapeutics for serious diseases with unmet medical needs. It specializes in discovering and advancing bio-therapeutics, with a primary focus on cancer and neurodegenerative disorders. Its lead product candidate, pepinemab, targets semaphorin 4D (SEMA4D) to potentially treat various cancers and neurodegenerative diseases like Alzheimer's and Huntington's disease.

DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.

RetiSpec is developing a non-invasive eye scanner for the early detection of Alzheimer’s Disease pathology years before symptoms occur. This enables clinicians to intervene with emerging therapeutics at an earlier stage when there's a chance of impacting the disease.

Founded in 2008 by Dr. Michela Gallagher, AgeneBio is a neuroscience pharmaceutical company dedicated to developing treatments for memory disorders. Its primary focus is on Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD), aiming to prevent neurodegeneration and preserve cognitive function.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Tetra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical drugs that target phosphodiesterase (PDE) subtype inhibitors for various neurological and non-neurological disorders. The company is advancing BPN14770, a novel therapeutic agent designed to enhance synaptic actions in the brain's neurons, which is particularly relevant for conditions affecting memory and cognition, such as Alzheimer's disease, schizophrenia, and developmental disabilities. Tetra Therapeutics aims to create effective treatments for patients suffering from Alzheimer's, other dementias, traumatic brain injury, and psychiatric disorders. Founded in 2011 and based in Grand Rapids, Michigan, the company was previously known as Tetra Discovery Partners and rebranded in August 2019. Tetra Therapeutics has established a strategic collaboration with Shionogi & Co., Ltd., and as of July 2020, operates as a subsidiary of Shionogi.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on drug discovery and development aimed at addressing metabolic diseases associated with aging. Founded in 2006 and based in Kalamazoo, Michigan, the company is dedicated to investigating novel molecular targets for therapeutic intervention. It is developing a range of innovative oral therapeutics, including MSDC-0160 and MSDC-0602, to treat conditions such as type 2 diabetes, polycystic kidney disease, and neurodegenerative disorders like Alzheimer's and Parkinson's diseases. The company's approach involves creating non-thiazolidinedione insulin sensitizers that modulate mitochondrial function to improve metabolic control, addressing complications related to insulin resistance and other aspects of metabolic syndrome.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.

Cambridge Cognition is a neuroscience digital health company specializing in the development of digital cognitive assessment solutions for pharmaceutical clinical trials and remote patient monitoring worldwide.

Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on drug discovery and development aimed at addressing metabolic diseases associated with aging. Founded in 2006 and based in Kalamazoo, Michigan, the company is dedicated to investigating novel molecular targets for therapeutic intervention. It is developing a range of innovative oral therapeutics, including MSDC-0160 and MSDC-0602, to treat conditions such as type 2 diabetes, polycystic kidney disease, and neurodegenerative disorders like Alzheimer's and Parkinson's diseases. The company's approach involves creating non-thiazolidinedione insulin sensitizers that modulate mitochondrial function to improve metabolic control, addressing complications related to insulin resistance and other aspects of metabolic syndrome.

Life Molecular Imaging is a diagnostic center specializing in neuroimaging and cardiovascular imaging services. The company develops novel PET tracers aimed at advancing molecular imaging research, thereby enhancing the early detection and characterization of chronic and life-threatening diseases. Its offerings include research and development laboratories, a network of cyclotrons, radiopharmacies, and imaging facilities, which facilitate access for physicians, the pharmaceutical industry, and academic institutions to both established and innovative imaging agents. This comprehensive approach supports improved therapeutic outcomes and enhances the capabilities of clinical trials and routine clinical practice.